Clinical Significance of Surgical Resection for the Recurrence of Esophageal Cancer After Radical Esophagectomy

Annals of Surgical Oncology

Volumn 22, Issue 1, 2015, Pages 240-246

  Hiyoshi, Yukiharu ^a   Morita, Masaru ^a   Kawano, Hiroyuki ^a   Otsu, Hajime ^a   Ando, Koji ^a   Ito, Shuhei ^a   Miyamoto, Yuji ^b   Sakamoto, Yasuo ^b   Saeki, Hiroshi ^a   Oki, Eiji ^a   Ikeda, Tetsuo ^a   Baba, Hideo ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER STAGING; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84936765674     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3970-5     Document Type: Article

References (32)

1. Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.
2. Matthews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg. 1986;73:621–3.
3. Skinner DB, Little AG, Ferguson MK, Soriano A, Staszak VM. Selection of operation for esophageal cancer based on staging. Ann Surg. 1986;204:391–401.
4. Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–33.
5. Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143–8.
6. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.
7. Morita M, Yoshida R, Ikeda K, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1,000 consecutive patients treated at a single institute. Surgery. 2008;143:499–508.
8. Morita M, Kuwano H, Ohno S, Furusawa M, Sugimachi K. Characteristics and sequence of the recurrent patterns after curative esophagectomy for squamous cell carcinoma. Surgery. 1994;116:1–7.
9. Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.
10. Motoyama S, Kitamura M, Saito R, Maruyama K, Okuyama M, Ogawa J. Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck. World J Surg. 2006;30:191–8.
11. Yano M, Takachi K, Doki Y, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus. 2006;19:73–7.
12. Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.
13. Ichikawa H, Kosugi S, Nakagawa S, et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery. 2011;149:164–70.
14. Takemura M, Sakurai K, Takii M, Yoshida K. Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome. J Cardiothorac Surg. 2012;7:103.
15. Chen F, Sato K, Sakai H, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.
16. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.
17. Law S, Kwong DL, Kwok KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–47; discussion 347–338.
18. Shimada H, Kitabayashi H, Nabeya Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.
19. Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31:1107–14.
20. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.
21. Oki E, Morita M, Kakeji Y, et al. Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer. Dis Esophagus. 2007;20:301–4.
22. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.
23. Morita M, Kumashiro R, Hisamatsu Y, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroentero. 2011;46:1284–91.
24. Kadota H, Fukushima J, Nakashima T, et al. Comparison of salvage and planned pharyngolaryngectomy with jejunal transfer for hypopharyngeal carcinoma after chemoradiotherapy. Laryngoscope. 2010;120:1103–8.
25. Ida S, Morita M, Hiyoshi Y, et al. Surgical resection of hypopharynx and cervical esophageal cancer with a history of esophagectomy for thoracic esophageal cancer. Ann Surg Oncol. 2014;21:1175–81.
26. Uchiyama H, Shirabe K, Morita M, et al. Expanding the applications of microvascular surgical techniques to digestive surgeries: a technical review. Surg Today. 2012;42:111–20.
27. Kato H, Nakajima M. The efficacy of FDG-PET for the management of esophageal cancer: review article. Ann Thorac Cardiovasc Surg. 2012;18:412–9.
28. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419–23.
29. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer Oxford Eng 1997;33:1216–20.
30. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.
31. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826–34.
32. Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin, and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307–13.